Compare DraftKings Inc (DKNG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

DraftKings (DKNG) trades at $19.58, down 7.4% recently and near a 52-week low of $18.95, reflecting bearish technical signals. The company achieved profitability in 2025 with $6.05B revenue and $3.71M net income, but Q2 2026 EPS missed estimates. Analyst consensus remains strongly bullish with a $33.13 price target, though high valuation multiples and recent earnings volatility pose concerns.

Long-term prospects are supported by revenue growth and strategic initiatives like the DKeX rollout and NHL sponsorship, targeting $1B EBITDA in 2026. However, risks include competitive pressures, regulatory uncertainty in markets like Brazil, and the stock's sensitivity to growth deceleration. Investors should weigh strong analyst optimism against fundamental execution risks.

Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.

The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.